Solventum said reported sales for Q4 2024 (3 months) increased 1.9% to $2.074 billion, and organic sales increased 2.3%. GAAP diluted earnings per share was $0.17, and adjusted EPS was $1.41.

1. 01

   Solventum said reported sales for Q4 2024 (3 months) increased 1.9% to $2.074 billion, and organic sales increased 2.3%. GAAP diluted earnings per share was $0.17, and adjusted EPS was $1.41.

2. 02

   For Q4, the company reported GAAP operating income of $136 million (operating margin 6.6%) and adjusted operating income of $422 million (20.4%). It cited lower gross margins, including the impact from the 3M supply agreement mark-up, and an increase in operating expenses related to public company stand-up costs and growth investments as factors in the operating margin decline.

3. 03

   Solventum said cash from operations for the full year 2024 (12 months) was $1,185 million, and free cash flow was $805 million. For Q4 (3 months), cash from operations was $219 million and free cash flow was $92 million.

4. 04

   The company provided full-year 2025 guidance of organic sales growth of +1.0% to +2.0%, adjusted EPS of $5.45 to $5.65, and free cash flow of $450M to $550M. The company said this guidance currently includes its Purification & Filtration segment. On February 25, 2025, it announced the sale of the Purification & Filtration segment and said it will update its annual guidance after the transaction closes.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.